MSACL 2018 US Abstract

Topic: Informatics & Analytics

On the Building of the Skyline Targeted Mass Spec Software

Brendan MacLean (Presenter)
University of Washington

Bio: Brendan worked at Microsoft for 8 years in the 1990s where he was a lead developer and development manager for the Visual C++/Developer Studio Project. Since leaving Microsoft, Brendan has been the Vice President of Engineering for Westside Corporation, Director of Engineering for BEA Systems, Inc., Sr. Software Engineer at the Fred Hutchinson Cancer Research Center, and a founding partner of LabKey Software. In this last position he was one of the key programmers responsible for the Computational Proteomics Analysis System (CPAS), made significant contributions to the development of X!Tandem and the Trans Proteomic Pipeline, and created the LabKey Enterprise Pipeline. Since August, 2008 he has worked as a Sr. Software Engineer within the MacCoss lab and been responsible for all aspects of design, development and support in creating the Skyline Targeted Mass Spec Environment and its grow

Authorship: Brendan MacLean
University of Washington

Short Abstract

The Skyline project started in August, 2008 as a 2-year effort to bring better SRM/MRM software tools to the NCI Clinical Proteomics Technology Assessment for Cancer (CPTAC) Verification Working Group that could support the variety of mass spectrometers in use in participating laboratories. Over 9 years later, the Skyline project is a thriving proteomics community open-source collaboration supporting 6 mass spec instrument vendors, integrated with a wide variety of external software, with thousands of users worldwide and many thousands of instances started each week with expanding support for small molecules, absolute quantification and ion mobility.

Long Abstract

This presentation will focus on key aspects of the 9 year open-source project which have made it successful and allowed it to grow and thrive without charging its users for the software, support or user education.

References & Acknowledgements:

Financial Disclosure

Board Memberno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above: